Dermatology

Meda has a portfolio of patents that include new formulations and new uses of imiquimod (the active ingredient in Aldara). In 2010, Meda also acquired exclusive rights in Europe to a new formulation of Aldara: a 3.75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). This product can be used on a significantly larger treatment area; it is also once-daily and more tolerable.

The patent for this novel imiquimod formulation is pending. The product was recently approved in Canada and the US and has been submitted for regulatory approval in other key markets.

The combination product containing clindamycin and tretinoin for the treatment of mild to severe acne is in the registration phase. Clindamycin and tretinoin in combination have shown greater efficacy for the treatment of inflammatory and non-inflammatory acne compared with each of the components as monotherapy.
Meda has acquired the European license.

Sotirimod is intended for treatment of conditions such as actinic keratosis and is a follow-up to Aldara (imiquimod). Sotirimod and imiquimod are immunomodulating agents that activate the body’s own immune defenses through the skin and help counteract skin changes such as actinic keratosis. Sotirimod is a proprietary substance in a late phase of clinical development. Sotirimod is more potent than imiquimod, and human trials have shown that it is more effective on actinic keratosis than Aldara.